Glide Pharma Announces Design Optimisation Agreement With Nypro Healthcare For Scale Up Of Solid Dose Delivery Device

OXFORD, England, July 2, 2013 /PRNewswire/ --



Glide Pharma today announced that it has entered an agreement with global device manufacturer Nypro Healthcare to complete the design optimisation of its solid dose injector in preparation for production scale up.  The company's delivery system, the Glide SDI®, is a unique technology for injecting drugs and vaccines in a solid dosage form without the need for a needle.  The Glide SDI® comprises a novel tiny solid dosage, which is pushed into the skin with a small, hand-held, spring-powered device.  Nypro Healthcare will work with Glide Pharma to ensure the design of the device and its components are optimised for manufacturing scale up and to ensure patient requirements, including self-administration, are met.

"This agreement marks a milestone for our Glide SDI® device as it will enable us to complete the final phase of development prior to production scale up.  As a recognized leader in the development and manufacturing of precision devices we believe that Nypro Healthcare is the perfect partner to work with Glide Pharma on advancing our novel delivery system," stated Dr Mark Carnegie-Brown, CEO, Glide Pharma.

"The Glide SDI® is a highly innovative delivery system, which is very different from other technologies currently on the market.  Nypro Healthcare is delighted to have been selected as Glide Pharma's partner to help progress the development of this exciting new technology," commented Chris Nother, VP Business Development, Nypro Healthcare.

About the Glide SDI® (Solid Dose Injector)

The Glide SDI® is an innovative needle-free delivery system.  The reusable injector uses a spring mechanism to administer a tiny solid dosage below the patient's skin, where it dissolves and releases the pharmaceutical.  Glide's solid dose formulations eliminate the risk of needle-stick injuries and avoid time-consuming reconstitution.  They also have the potential to modify the release of medicines and to improve stability, removing the need for refrigeration.  The one-click action, pen-sized device is extremely easy to use, with medicines supplied in pre-filled disposable cassettes, making it ideal for self-administration.  In clinical testing, volunteers strongly preferred the Glide SDI® to traditional needle and syringe.

About Glide Pharma

Glide Pharma is a pharmaceutical development and device company focused on the easy, safe and convenient administration of solid dose formulations of therapeutics and vaccines.  The company has a range of in-house and partnered programmes based on its proprietary solid dose injector, the Glide SDI®.  Glide Pharma has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors.  The company has successfully completed five investment rounds, and is supported by a consortium of institutional and private technology investors, including Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT.  For more information please visit http://www.glidepharma.com.

About Nypro Healthcare

Nypro Healthcare is a provider of device development and global manufacturing services to the world's leading and emerging pharmaceutical, diagnostics and medical device companies, supporting from concept, through clinical trials and into commercial production.  Nypro Healthcare is an operating unit of Nypro Inc., a global plastics and contract manufacturer with $1.2 billion annual revenues, which recently agreed to merge with Jabil Circuit Inc., a $17 billion electronics products solutions company.  For more information please visit http://www.nypro.com.

Contacts
Dr Mark Carnegie-Brown
Chief Executive
Glide Pharma
Tel: +44(0)8700-853700

Rob Budge
RJB Communications
Tel: +44(0)1865-760969
Mobile: +44(0)7710-741241

SOURCE Glide Pharma